Document Type
Article
Publication Date
2-13-2026
Abstract
ASCPT has a mission to advance clinical pharmacology and translational sciences to reduce health disparities. The development, regulatory, and outcomes (DRO) network within ASCPT strives to advance pharmacoequity globally. Pharmacoequity, coined by Utibe Essien (2021), is the principle that all individuals, regardless of race, ethnicity, geography, or socioeconomic status, should have access to high-quality and evidence-based therapies. This perspective spotlights the network's contributions toward this goal and identifies priority areas to build equitable health outcomes.
Publisher Attribution
© 2026 The Author(s). Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Recommended Citation
Jayachandran, Priya; Ladumor, Mayur K.; Vlasakakis, Georgios; Riselli, Andrew; Ilic, Katarina V.; van Wijk, Rob C.; Elmeliegy, Mohamed; Mukker, Jatinder Kaur; Sawant-Basak, Aarti; Long, Tao; Dong, Juyao; Rayad, Noha; Zhang, Tao; and DRO Network, "Advancing Pharmacoequity Globally: Reflections from the ASCPT Development, Regulatory, and Outcomes Network" (2026). Pharmacy Faculty Scholarship. 103.
https://orb.binghamton.edu/pharmacy_fac/103
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-No Derivative Works 4.0 International License.
Comments
https://doi.org/10.1002/cpt.70237